Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients

Background CD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, we initiated a clinical trial with in-house produced CD19 C...

詳細記述

書誌詳細

主要な著者:	Elad Jacoby, Orit Itzhaki, Abraham Nissani, Michal Levi, Arnon Nagler, Adva Kubi, Karin Brezinger, Hadar Brayer, Li-at Zeltzer, Meir Rozenbaum, Helly Vernitsky, Amos Toren, Abraham Avigdor
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMJ Publishing Group 2020-05-01
シリーズ:	Journal for ImmunoTherapy of Cancer
オンライン･アクセス:	https://jitc.bmj.com/content/8/1/e000148.full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!